Completed PHASE2 INTERVENTIONAL 2-arm NCT01004016

A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

A Double-blind, Placebo-controlled, Crossover Study, Followed by Open-label Study of KPS-0373 in Patients With SCD

Sponsor: Kissei Pharmaceutical Co., Ltd.

Updated 5 times since 2017 Last updated: Sep 27, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Spinocerebellar Degeneration and is currently completed. Kissei Pharmaceutical Co., Ltd. leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kissei Pharmaceutical Co., Ltd.

Data source: Kissei Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Japan, Japan